Dual Donor Liver Transplantation in Korea

At a Glance

Overview

Dual-donor living donor liver transplantation (DD-LDLT) is a surgical solution developed when a single living donor cannot safely provide a graft large enough for an adult recipient.

In standard living donor liver transplantation, the donor gives either a right or left lobe. If the donor's liver is too small — or if donating the required volume would leave the donor with an unsafe remnant — the transplant cannot proceed.

DD-LDLT resolves this by recruiting two separate living donors. Each donor undergoes a partial hepatectomy, typically donating either two left-lobe or left-lateral-segment grafts, or one right lobe and one left lobe. The two grafts are implanted together into the recipient, whose native liver has been removed.

The combined graft volume meets the recipient's metabolic needs while each individual donor retains a safe remnant liver.

Korea pioneered this technique in 2000 and has accumulated the world's largest institutional experience. Published outcomes show that long-term recipient survival in DD-LDLT is comparable to conventional single-donor LDLT when performed at high-volume centers.

The procedure is technically demanding — operative time for the recipient surgery alone typically ranges from 14 to 20 hours — and is offered only at specialized hepatobiliary units with dedicated transplant teams and high-dependency infrastructure.

Am I a Candidate?

DD-LDLT is considered when all three of the following conditions apply: the recipient has end-stage liver disease or hepatocellular carcinoma within accepted transplant criteria; a single living donor is available but cannot safely provide adequate graft volume; and two willing, medically suitable donors exist.

Typical recipient indications include:

• Liver cirrhosis (viral, alcoholic, autoimmune, or metabolic origin)
• Hepatocellular carcinoma meeting transplant criteria
• Acute-on-chronic liver failure requiring urgent transplant
• Metabolic liver disease causing systemic complications

Each prospective donor undergoes extensive independent evaluation:

• Volumetric CT to confirm adequate remnant liver after planned resection
• Full blood-group and cross-match compatibility workup
• Psychological assessment to confirm voluntary, informed consent
• Cardiopulmonary fitness screening

Candidates are excluded if either donor's remnant would fall below safe thresholds, if the recipient has uncontrolled systemic infection, or if extrahepatic malignancy is present.

Because three people undergo major surgery in the same operative window, the ethics review and multidisciplinary case conference requirements are more rigorous than for standard LDLT. Korean transplant centers have established institutional protocols for this review process.

How the Procedure Works

Pre-operative preparation spans several weeks. The recipient, donor A, and donor B each complete independent work-ups. Volumetric imaging maps each donor's anatomy; the surgical team plans resection planes and graft implantation sequence before any incisions are made.

On the day of surgery, the two donor hepatectomies typically proceed sequentially or in parallel in adjacent theatres, timed so both grafts are ready for back-table preparation before recipient hepatectomy is completed.

Donor surgery (each donor):

• General anesthesia; laparoscopic-assisted or open approach depending on anatomy
• Careful dissection and division of the designated hepatic lobe or segment
• Bile duct and vascular pedicle division with meticulous hemostasis
• Graft flushed and placed on ice; donor abdomen closed

Recipient surgery:

• Diseased native liver removed (total hepatectomy)
• Vascular reconstruction for each graft: portal vein, hepatic artery, hepatic vein anastomoses performed in sequence
• Both grafts positioned in the abdominal cavity — typically one in the right anatomical position, one in the left, or both in a modified configuration
• Biliary reconstruction (hepaticojejunostomy or duct-to-duct) for each graft
• Abdominal closure with drains in situ

Post-operatively, the recipient is transferred to ICU. Immunosuppression begins immediately. Each graft is monitored with daily liver-function tests and Doppler ultrasound to confirm vascular patency and graft regeneration.

Recovery Timeline

ICU phase (days 1–5): The recipient is closely monitored for primary graft function, vascular complications, and bleeding. Each donor is also monitored in a high-dependency setting for the first 24–48 hours.

Ward phase (weeks 1–4): Once haemodynamically stable, the recipient transfers to the transplant ward. Liver enzymes, bilirubin, and coagulation are tracked daily, then every few days. Oral immunosuppressants are titrated. Physical therapy begins gently.

• Donors are typically discharged within 7–10 days if recovery is uncomplicated
• Recipients remain in-hospital for 2–3 weeks on average; longer if rejection or biliary complications require intervention

Outpatient phase in Korea (weeks 4–12): After hospital discharge, the recipient attends outpatient clinic two to three times per week initially, then weekly. Tacrolimus or cyclosporine trough levels are monitored closely. Liver biopsy may be performed if rejection is suspected.

International patients are cleared to fly home only after the transplant team confirms stable graft function, no active complications, and an established immunosuppression regimen the local team can manage.

Long-term recovery:

• Light activity resumes around months 3–4
• Return to desk work: approximately 3–6 months
• Full physical recovery and stabilised immunosuppression: 6–12 months
• Lifelong immunosuppression and annual follow-up are required

Cost Breakdown

Liver transplant costs in Korea for international patients are generally estimated in the range of $130,000–$170,000 for DD-LDLT, reflecting the significantly greater surgical complexity versus standard single-donor LDLT.

This range is approximate and varies by center, recipient complexity, length of ICU stay, and whether complications require re-intervention.

Typical inclusions in transplant packages at major Korean centers:

• Pre-transplant evaluation for recipient and both donors (imaging, labs, cardiology, psychology)
• All three surgeries (recipient hepatectomy and implantation, two donor hepatectomies)
• ICU and ward stays for recipient and both donors
• Initial immunosuppressive medications during hospitalization
• Outpatient follow-up visits during the Korea stay
• Interpreter and international patient coordinator services

Typical exclusions:

• Long-term immunosuppressive drugs after discharge
• Airfare and accommodation for patient and accompanying family
• Re-admission costs if complications arise after discharge
• Follow-up care in the home country

For context, comparable transplant surgery in the United States is estimated at $500,000–$600,000 or more before insurance adjustments.

Patients should request an itemized estimate from the international patient department of their chosen center before committing, as dual-donor cases are quoted individually rather than from a fixed package price.

Why Korea

Korea performed the world's first dual living donor liver transplantation in March 2000, a landmark that established the country as the global pioneer of this technique.

In the decades since, Korean hepatobiliary teams have refined donor selection criteria, graft combination strategies, and vascular reconstruction sequences to a degree unmatched outside East Asia.

Korea has the highest rate of living donor liver transplantation per capita in the world, according to IRODaT data. This volume translates directly into surgical precision: scrub nurses, anesthesiologists, perfusionists, and hepatologists work together in teams that perform multiple LDLT cases each week, not each year.

Several structural advantages reinforce Korea's position:

• Tertiary-center infrastructure: Seoul's major transplant hospitals operate dedicated hepatobiliary ICUs, on-site pathology for rapid frozen sections, and 24-hour vascular surgery backup — all essential when three simultaneous major surgeries are involved
• Regulatory framework: The Korean Health Industry Development Institute (KHIDI) and the Medical Korea program actively support inbound medical tourism with standardized quality audits and international patient coordinators
• Published evidence base: Korean surgeons have authored much of the peer-reviewed literature on dual-graft outcomes, graft regeneration kinetics, and ABO-incompatible dual-graft protocols
• Cost efficiency: Korea achieves outcomes comparable to top Western centers at 20–30% of the equivalent U.S. price, without compromising on implant quality, ICU standards, or nursing ratios

For patients who cannot access a deceased-donor liver in their home country and lack a single donor with sufficient liver volume, Korea's DD-LDLT program represents one of the few viable options in the world.

Related Topics

Sources

• Living donor liver transplantation using dual grafts from two donors — PubMed
• Dual-graft adult living donor liver transplantation — PubMed
• Regeneration and outcome of dual grafts in living donor liver transplantation — PubMed
• Current status and outcome of liver transplantation in South Korea — PMC
• Medical Korea — Transplantation (official government portal)

Top Hospitals